Insider · CIK 0001812511
Susan Rodriguez
Files at HRTX (HERON THERAPEUTICS, INC. /DE/), AVDL (AVADEL PHARMACEUTICALS PLC), MDRX (Veradigm Inc.), ARDX (ARDELYX, INC.), MNPR (Monopar Therapeutics). First filing Nov 22, 2023, latest Nov 22, 2023.
In brief
Susan Rodriguez files SEC Form 4 as director and COO at ARDX (ARDELYX, INC.), and also at HRTX (HERON THERAPEUTICS, INC. /DE/), AVDL (AVADEL PHARMACEUTICALS PLC), MDRX (Veradigm Inc.), MNPR (Monopar Therapeutics). Since Nov 22, 2023, Susan Rodriguez has reported 0 open-market buys worth $0 and 1 open-market sell worth $21k, the latest filed on Nov 22, 2023.
A track record needs three past buys with six months of prices behind them; Susan Rodriguez has 0, so none is measured yet.
The newest scored trade: sold $21k of ARDX on Nov 20, 2023, filed Nov 22, 2023, scored 30 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARDX: ARDELYX, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | ARDELYX, INC. | $21k 4,714 shares | -1% | +155% from low-12% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | MDRX Veradigm Inc. | AGrant or award Common Stock | +42,507 | $0.00 | $0 | 131,125 | Jun 3, 2026 |
| Mar 2, 2026 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +48,728 | $0.00 | $0 | 48,728 | Mar 4, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | - | - | 0 | Feb 12, 2026 |
| Jun 2, 2025 | MDRX Veradigm Inc. | AGrant or award Common Stock | +46,512 | $4.30 | $200k | 88,618 | Jun 3, 2025 |
| May 13, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | May 13, 2025 |
| Jan 30, 2025 | HRTX HERON THERAPEUTICS, INC. /DE/ | AGrant or award Common Stock | +17,950 | $0.00 | $0 | 87,180 | Feb 3, 2025 |
| Jan 30, 2025 | HRTX HERON THERAPEUTICS, INC. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +35,900 | $1.73 | $62k | 35,900 | Feb 3, 2025 |
| Nov 20, 2023 | ARDX ARDELYX, INC. | SOpen-market sale Common Stock | -4,714 | $4.36 | $21k | 346,973 | Nov 22, 2023 |
Questions about Susan Rodriguez
Answered from the filings on this page, as of the latest one.
Is Susan Rodriguez buying or selling?
Not in the last 12 months. Susan Rodriguez's latest open-market trade on SEC Form 4 was sold $21k of ARDX on Nov 20, 2023.
How did Susan Rodriguez's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Susan Rodriguez has 0.
Where does Susan Rodriguez file Form 4?
Susan Rodriguez has filed Form 4 at ARDX (ARDELYX, INC.) as Chief Commercial Officer; HRTX (HERON THERAPEUTICS, INC. /DE/); AVDL (AVADEL PHARMACEUTICALS PLC) as Chief Operating Officer; MDRX (Veradigm Inc.); MNPR (Monopar Therapeutics) as CCSO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.